ResourceLife Sciences
A Semi-Automated, Non-Radioactive Assay for the Detection of Antibody-Based Complement-Dependent Cytotoxicity
6 Aug 2013Pharmaceutical companies are increasingly focused on biologic therapeutics rather than biochemical, chemical and radiological compounds for many cancer treatments. Biologic therapeutics only target and destroy specific cancer cells, thus preventing damage to surrounding, healthy cells and reducing unwanted cytotoxic events. In this application note read about the use of a non-radioactive, bioluminescent antibody-based Complement-Dependent Cytotoxicity (CDC) assay.
Links
Tags
Cell-Based AssaysCell-based assays are used to monitor the presence, quantity and activities of a desired cellular analyte including drug molecules or biomarkers. This can reveal information on cell health (apoptosis, cytotoxicity, viability and proliferation assays), cell metabolism, cell migration and cell signaling mechanisms. Find the best cell-based assay products, kits and equipment with our peer reviewed product directory: compare products, check customer reviews and receiving pricing direct from manufacturers.CytotoxicityCytotoxicity assays measure the toxic effects of substances on cells, often used in drug testing and environmental studies. These tests are crucial in determining the safety of chemicals and pharmaceutical compounds. Explore cytotoxicity testing tools in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.